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Objectives. We attempted to determine the relative risks and 
benefits of percutaneous transluminal coronary angioplasty 
(PTCA) and repeat coronary artery bypass grafting (re-CABG) in 
patients with previous coronary bypass urgery (CABG). 
Background. Due to an expanding population of patients with 
surgically treated coronary artery disease and the natural pro- 
gression of atherosclerosis, anincreasing number of patients with 
previous CABG require repeat revascularization procedures. Al- 
though there are randomized comparative data for CABG versus 
medical therapy and, more recently, versus PTCA, these studies 
have excluded patients with previous CABG. 
Methods. We retrospectively analyzed ata from 632 patients 
with previous CABG who required either elective re-CABG (n = 
164) or PTCA (n = 468) at a single center during 1987 through 
1988. The PTCA and re-CABG groups were similar with respect to 
gender (83% vs. 85% male), age >70 years (21% vs. 23%), mean 
left ventricular ejection fraction (46% vs. 48%), presence of class 
IlI or 1V angina (70% vs. 63%) and three-vessel coronary artery 
disease (77% vs. 74%). 
Results. Complete revascularization was achieved in 38% of 
patients with PTCA and 92% of those with re-CABG (p < 0.0001). 
The in-hospital complication rates were significantly lower in the 
PTCA group: death (0.3% vs. 7.3%, p < 0.0001) and Q wave 
myocardial infarction (MI) (0.9% vs. 6.1%, p < 0.0001). Actuarial 
survival was equivalent at 1 year (PTCA 95% vs. re-CABG 91%) 
and 6 years (PTCA 74% vs. re-CABG 73%) of follow-up (p = 0.32). 
Both procedures resulted in equivalent event-free survival (free- 
dom from death or Q wave MI) and relief of angina; however, the 
need for repeat percutaneous or surgical revascularization, or
both, by 6 years was significantly higher in the PTCA group 
(PTCA 64% vs. re-CABG 8%, p < 0.0001). Multivariate analysis 
identified age >70 years, left ventricular ejection fraction <40%, 
unstable angina, number of diseased vessels and diabetes mellitus 
as independent correlates of mortality for the entire group. 
Conclusions. In this nonrandomized series of patients with 
previous CABG requiring revascularization, an initial stategy of 
either PTCA or re-CABG resulted in equivalent overall survival, 
event-free survival and relief of angina. PTCA offers lower proce- 
dural morbidity and mortality risks, although it is associated with 
less complete revascularization a d a greater need for subsequent 
revascularization procedures. 
(J Am Coil Cardiol 1996;28:1140- 6) 
The number of patients with previous coronary artery bypass 
grafting (CABG) requiring repeat revascularization proce- 
dures is steadily increasing (1). Consequently, clinicians in- 
creasingly face the challenge of recommending a percutaneous 
or repeat surgical approach to revascularization. Comparative 
randomized data are available for CABG versus medical 
therapy (2-4) and, more recently, for CABG versus percuta- 
neous transluminal coronary angioplasty (PTCA) (5-9). How- 
ever, patients with previous CABG have generally been ex- 
cluded from these studies, and thus the relative etficacies of 
PTCA and repeat CABG (re-CABG) in patients with previous 
CABG are uncertain. This information is important for clinical 
decision making because re-CABG has been associated with 
greater morbidity and mortality than initial CABG (10,11). In 
contrast, PTCA in patients with previous CABG has been 
associated with procedural mortality rates comparable to those 
of PTCA in patients without prior CABG (12,13) despite the 
technical challenges presented by older grafts with complex 
atherosclerotic disease (14). 
The purpose of this study was to determine the relative risks 
and benefits of PTCA versus re-CABG in patients with previ- 
ous CABG. 
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Methods  
Patients. This study was a retrospective analysis of 632 
consecutive patients with previous CABG who underwent 
elective re-CABG (n = 164) or PTCA (n = 468) between 
January 1, 1987 and December 31, 1988. All percutaneous and 
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Abbreviations and Acronyms 
CABG : coronary artery, bypass grafting 
CCS - Canadian Cardiovascular Society 
ECG - e lectrocardiogram 
MI - myocardial  infarction 
PTCA = percutaneous transluminal coronary angioplasty 
re -CABG - repeat coronary artery bypass grafting 
repeat surgical revascularization procedures were performed 
at the Mid America Heart Institute of Saint Luke's Hospital in 
Kansas City, Missouri. Patients presenting with acute myocar- 
dial infarction (MI) as manifested by chest pain and electro- 
cardiographic (ECG) evidence of ST segment elevation were 
excluded, as were all emergency re-CABG procedures, The 
groups were matched for 1) gender; 2) age >70 years; 3) left 
ventricular systolic function (as measured by ejection fraction); 
4) three-vessel native coronary artery disease; 5) Canadian 
Cardiovascular Society (CCS) functional c ass III or IV angina. 
Definitions. Q wave MI was defined as ECG appearance of 
new Q waves upported by creatine kinase MB fraction enzyme 
elevation. In-hospital death was defined as all-cause mortality 
during the index hospital stay. Baseline left ventricular ejection 
fraction was documented byventriculography at cardiac cath- 
eterization, transthoracic echocardiography or rest radionu- 
clide ventriculography. Significant stenosis was defined as any 
lesion in a major epicardial coronary artery or branch vessel 
(->2.0 mm in diameter) that by visual angiographic assessment 
demonstrated ->50% narrowing of lumen diameter. Three- 
vessel native coronary artery disease was defined as significant 
stenosis in each of the three major epicardial coronary arteries 
or their corresponding branch vessels. PTCA procedural suc- 
cess was defined as <50% residual stenosis in all lesions 
attempted without the occurrence of a major complication 
(death, Q-wave MI, emergency CABG). Incomplete revascu- 
larization was defined as the presence of any lesion with ->50% 
lumen diameter stenosis in a major epicardial coronary artery 
or branch (->2.0 mm in diameter) whose dilation either was not 
attempted orwas unsuccessful during PTCA procedure, or was 
not bypassed uring CABG or re-CABG. In the multivariate 
analysis, unstable angina was defined as CCS class IV symp- 
toms. 
Coronary angioplasty procedure. PTCA was performed by 
previously described standard techniques (15). Complete re- 
vascularization through dilation of all angiographically signif- 
icant stenoses during a single procedure was attempted when- 
ever possible. Patients were pretreated with aspirin, 325 mg. At 
the beginning of the procedure an intravenous bolus injection 
of 10,000 U of heparin was given, followed by a bolus of 5,000 
U/h of elapsed time during the procedure. Intravenous diaze- 
pam and morphine sulfate were administered asneeded for 
sedation. Aspirin, 325 nag daily, was continued indefinitely 
after the procedure. 
CABG. Patients underwent CABG with standard tech- 
niques using anterograde or retrograde, or both, cold cardio- 
plegia in accordance with surgeon preference. Whenever pos- 
sible, the left internal mammary artery graft was utilized to 
bypass the left anterior descending coronary artery. Reversed 
saphenous vein graft segments were generally used to bypass 
diseased vessels in the left circumflex or right coronary artery 
systems. Patients were discharged on a regimen of aspirin, 
325 mg daily. 
Follow-up. Prospective long-term follow-up data were ob- 
tained from mailed questionnaires, telephone interviews and 
subsequent office visits. This information was recorded in a 
computer data base and updated on a systematic, periodic 
basis. Follow-up data were available for 95.4% of the patients. 
The mean _+ duration of the follow-up period was 48 ± 21 
months. 
Statistical analysis. Demographic, clinical and anglo- 
graphic data were compared by using the Student test, 
chi-square test or Fisher exact test where appropriate. All 
reported p values were two-tailed. Long-term actuarial survival 
tables were constructed on an intention-to-treat b sis with use 
of the Kaplan-Meier method. Late results were compared by 
using univariate actuarial (life-table) and multiple regression 
Cox proportional hazards analyses. Variables entered in the 
Cox regression equation included age >70 years, gender, left 
ventricular ejection fraction <40%, number of diseased ves- 
sels, diabetes mellitus, history of previous MI, presentation 
with unstable angina, presence of left anterior descending 
coronary artery disease, use of the left internal mammary 
artery, extent of revascularization, graft age at reoperation, 
re-CABG and PTCA. 
Results  
The data of 632 consecutive patients requiring repeat 
revascularization procedures after previous CABG were re- 
viewed. During the index hospital admission, 468 patients 
underwent 643 PTCA procedures, and elective re-CABG was 
performed in 164 patients. These procedures represented 26% 
(468 of 1,803) of all PTCA procedures and 16% (164 of 1,033) 
of all CABG operations performed at our institution during 
this time period. The demographic and clinical characteristics 
of the two clinical groups are described in Table 1. The mean 
age was similar, and there was no significant difference in the 
percent of patients >70 years of age in either group (PTCA 
21% vs. re-CABG 23%, p = 0.78). The gender mix was 
equivalent in the two patient groups, and the majority of 
patients were male. Advanced anginal symptoms were com- 
monly present at the time of the procedure; however, a 
significantly greater number of patients with CCS functional 
class IV symptoms were treated with PTCA versus re-CABG 
(45.8% vs. 26.2%, p < 0.0001). Nearly 75% of the patients in 
both groups had three-vessel native coronary artery disease, 
and -20% of patients in both groups had diabetes mellitus. 
The mean left ventricular ejection fractions were similar 
between the groups, despite the significantly greater propor- 
tion of PTCA-treated patients with a history of previous MI 
(56.0% vs. 41.5%, p < 0.0001). The mean graft age in both 
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Table 1. Baseline Patient Demographics and Clinical Characteristics 
PTCA Re-CABG 
Group Group 
(n = 468) (n = 164) p Value 
Mean agc (yr) 62.3 _+ 9.0 63.6 _+ 8.6 0.1 
Age >70 yr 21.2% 22.6% 0.78 
Male 82.7c/~ 84.8% 0.63 
CCS angina class III or IV 69.7% 63.4% 0.15 
CCS angina class IV 45.8% 26.2% <O.0001 
Mean LVEF 45.8 _+ 23.7% 48.2 _+ 14.5% 0.3 
3-vessel CAD 76.5% 73.8% 0.74 
Prior MI 56.0% 41.5% <0.0(101 
Diabetes mellitus 19.4% 21.3% 0.65 
Mean graft age (too) 79.7 + 51.6 106.8 + 48.2 <0.0001 
Data presented are mean valuc _+ SD or percent of patient group. CAD 
coronary artery disease; CCS - Canadian Cardiovascular Society; LVEF = left 
ventricular ejection fraction; MI - myocardial infarction; n = number of 
patients; PTCA - percutaneous transluminal coronary angioplasty; Re- 
CABG - repeat coronary artery' bypass grafting. 
groups was >7 years, although patients who underwent re- 
CABG had significantly older grafts than those in the PTCA 
group (106.8 ± 48.2 vs. 79.7 _+ 51.6 months, p < 0.0001). 
Procedural results. PTCA. Patients with significant steno- 
ses of the left main coronary artery (both protected and 
unprotected) or left main equivalent disease were not excluded 
from the PTCA group, and their lesions represent 2.9% (40 of 
1,376) of the lesions dilated. Saphenous vein graft lesions 
represented 19% (262 of 1,376) of the lesions dilated and the 
native circulation represented 81% (1,114 of 1,376). The mean 
number of lesions dilated per patient was 2.9 - 1.8. The 
procedural success rate was 94.9%. 
Re-CABG. The left internal mammary artery was used for 
58.5% (96 of 164) of re-CABG procedures. The mean number 
of new grafts placed and new distal anastomoses constructed 
was 2.2 _+ 0.75 and 3.1 ± 1.2, respectively. 
In-hospital complications. Major in-hospital complications 
occurred more frequently in the re-CABG group (Fig. 1). 
Death during the initial hospital stay occurred in 2 patients 
treated with PTCA (0.3%) versus 12 (7.3%) of those with who 
underwent re-CABG (p < 0.0001). Q wave MI was also 
significantly more frequent in the re-CABG group (6.1% vs. 
0.9%, p < 0.0001). 
Table 2 lists the primary cause of in-hospital death for all 
patients who failed to survive the revascularization procedure. 
The mean saphenous vein graft age of the two patients with 
PTCA who died was 12.5 years. One of these patients died 
during dilation of an unprotected left main coronary artery 
stenosis. The mean left ventricular ejection fraction and graft 
age of the 12 patients with re-CABG who died was 41.0 ± 12% 
and 9.4 ± 3.5 years, respectively. In the re-CABG group, 50% 
(6 of 12) of the deaths occurred in the operating room or 
within 24 h of the procedure. The majority of these deaths 
were associated with inadequate restoration of myocardial 
function despite maximal mechanical nd pharmacologic sup- 
port and an apparently technically successful procedure. An 
E 
N: 6 10 2 12 
Q-Wave Myocardial Death 
Infarction 
Figure 1. Number (N) and percent of major in-hospital events in 
patients with previous CABG treated with PTCA or re-CABG. Rates 
of both Q wave MI and death were significantly lower (p < 0.0001) in 
the patients reated with PTCA. Striped bars - PTCA; solid bars = 
re-CABG. 
additional three patients were classified as having a late cardiac 
death (>24 h after the procedure), and three patients died 
from complications of sepsis after a long stay in the intensive 
care unit. Thirty-three percent (4 of 12) of the deaths in the 
re-CABG group occurred in patients with advanced class IV 
symptoms at the time of their procedure. 
Long-term follow-up. Overall actuarial survival was equiv- 
alent with both PTCA and re-CABG at 1 year (95% vs. 91%) 
and 6 years (74% vs. 73%) of follow-up (p = 0.32) (Fig. 2). 
There was no significant difference in angina class between the 
two groups at a mean follow-up interval of 4 years; angina 
status in both groups was better than that immediately before 
the procedure (Table 3). 
Although both groups demonstrated quivalent relief of 
angina, patients treated with PTCA achieved significantly ess 
complete revascularization (PTCA 38% vs. re-CABG 92%, 
p < 0.0001) and required more additional revascularization 
procedures (PTCA or re-CABG, or both) over the ensuing 
6-year follow-up period (Fig. 3). Of the PTCA-treated pa- 
tients, 46% (214 of 468) underwent repeat angioplasty, 16% 
(74 of 468) ultimately required CABG and 9% (40 of 468) had 
both procedures. In the re-CABG group, 6 patients (3.7%) 
required subsequent PTCA, and only 2.4% (4 of 164) under- 
went a second re-CABG. There was no significant difference in 
event-free survival (freedom from death or Q wave MI) 
between the PTCA and re-CABG groups (Fig. 4). The 
follow-up analyses of both groups were performed in both a 
censored and an uncensored fashion. No statistically significant 
differences were noted between the two analyses in regard to 
the major long-term clinical end points of death, event-free 
survival and need for repeat revascularization. 
Multivariate analysis using Cox proportional hazards meth- 
odology identified age >70 years, left ventricular ejection 
fraction <40%, unstable angina, number of diseased vessels 
and diabetes as independent correlates of overall mortality 
(Fig. 5). 
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Table 2. Clinical Characteristics of Patients Who Died in the Hospital 
CCS 
Pt Angina Graft Primao' Causc Time 
No. Age (yr)/Gendcr LVEF Class Age (yr) of Death of Death 
PTCA 
1 63/M N/A IIl 13 Cardiac In lab 
2 58/M N/A I11 12 Cardiac PP day 1 
Mean 60.5 12.5 
Re-CABG 
1 59/F 61% II 15 Cardiac <24 h PP 
2 65/M 45'7~ III 7 Cardiac [n OR 
3 80/F 60~:~ IV g Cardiac In OR 
4 57/M 41% Ill 15 Cardiac In OR 
5 75/M 525:~- Ill 6 Cardiac In OR 
6 67/F 35q/ Ill t) Sepsis syndrome PO day 42 
7 63/M 259~- Ill 4 Cardiac PO day 2 
8 67/M 459~ lit 12 Cardiac PO day 6 
9 67/M 35(rc IV 9 Cardiac <24 h PP 
10 65/M 255:} IV 11 Cardiac PO day 18 
11 72/M 3892 IV 6 Sepsis syndrome PO day 33 
12 77/M 30ff Ill 10 Sepsis syndrome PO day 22 
Mean _+ SD 67.8 4l.(l~,b 9.4 
7.0 I2.2% 3.5 
F = female: lab = catheterization laboratory; M = male: N/A = not availablc; OR = operating room; PO = 
postoperative: PP = post procedure: Pt = patient: other abbreviations as in Table 1, 
Discussion 
The continual refinement of medical and surgical therapies 
for coronary artery disease has contributed to a significant 
reduction in cardiovascular morbidity and mortality in recent 
decades (16). In turn, a greater number of patients who have 
undergone previous CABG now present with clinical syn- 
dromes requiring consideration of repeat revascularization 
(17). The decision to pursue re-CABG or revascularization 
with PTCA is often difficult, and few comparative data are 
available to guide the clinician with this recommendation (18). 
Clinical background. The importance of this issue is un- 
derscored by the well established increased morbidity and 
mortality associated with re-CABG (10,11,19,20). Procedural 
mortality, ventricular arrhythmias, excessive bleeding, pro- 
longed ventilatory support, intraaortic balloon pump insertion 
Figure 2. Overall survival (including in-hospital mortality) in patients 
with previous CABG treated with PTCA or rc-CABG. There was no 
significant difference in overall actuarial survival between the two 
groups (p - 0.32). N = number of patients. 
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and perioperative myocardial infarction are all more prevalent 
after re-CABG than after the initial CABG (10,11). In addi- 
tion, patients undergoing re-CABG have been reported to 
have decreased long-term survival and to experience signifi- 
cantly greater recurrent angina than those undergoing initial 
CABG (11). Factors responsible for the higher likelihood of 
adverse outcomes with re-CABG are numerous and reflect 
both the greater technical challenges presented by a reopera- 
tion, as well as the frequent presence of high risk clinical 
features such as left main coronary artery disease, advanced 
age, class llI or 1V anginal symptoms, left ventricular dysfunc- 
tion and other comorbid illnesses (21). Even at institutions 
with extensive experience in re-CABG, the risk of in-hospital 
death and nonfatal Q wave MI is triple that of the initial 
operation (21,22). 
Given the inherent risks of re-CABG, PTCA has been used 
as an alternative revascularization approach. A compilation of 
reported data on >2,000 patients who underwent saphenous 
Table 3. Baseline and Follow-Up Symptomatic Status 
Preprocedurc Baseline 
Follow-Up Interval 
(mean 4 yr) 
CCS PTCA Re-CABG PTCA Re-CABG 
Angina Class (n = 468) (n = 164) (n = 372)* (n = 99) 
I~/l 12(:/- 9% 51% 62% 
It 18c:~ 28% 26% 18% 
Ill 24~/i 379; I0% 11% 
IV 46%1" 26% 13% 9% 
*p = 0.3 at follow-up for entire group (PTCA vs. Rc-CABG). lp < 0.000l 
at baseline (PTCA vs. Re-CABG). Abbreviations as in Table 1. 
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Figure 3. Actuarial analysis of revascularization durability. In patients 
with previous CABG, an initial treatment s rategy of PTCA rather 
than re-CABG resulted in a significantly greater need for repeat 
revascularization (PTCA or CABG, or both) at 6 years of follow-up 
(PTCA 64% vs. re-CABG 8%, p < 0.0001). N = number of patients. 
vein graft PTCA from 1979 to 1992 (23) revealed an overall 
procedural success rate of 90%, with a 0 to 2.5% rate of Q 
wave MI, a 0.3% to 5.0% incidence rate of emergency CABG 
and an overall mortality rate of 0.8%. Although in many cases 
these were selected patients with anatomic features favorable 
for PTCA, the results are comparable to those of more recent 
data for native artery PTCA (24) showing procedural success 
rates >90% and major complication rates (death, Q wave MI, 
emergency CABG) <4.0%. 
Clinical trials. To date, available published data from 
randomized trials of PTCA versus CABG describe results for 
patients with multivessel coronary artery disease and no prior 
bypass urgery (5-8). Although these trials have provided, and 
continue to provide, valuable clinical information, their appli- 
cation to patients with previous CABG is limited because such 
patients were systematically excluded from enrollment. 
Major procedural complications. The 7.3%, in-hospital 
mortality rate for re-CABG is comparable to mortality rates 
reported from other experienced centers during this time 
period (1,10,11,21,22,25-30), and it may partly reflect the 
severity of atherosclerotic heart disease in the surgical cohort. 
Figure 4. Event-•e survival from hospital discharge in patients with 
previous CABG treated with PTCA or re-CABG. There was no 
significant difference in the freedom from death or Q wave MI 
between the two groups over the 6-year follow-up period (p = 0.54). 
N - number of patients. 
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Figure 5. Multivariate correlates of long-term mortality in patients 
with previous CABG treated with PTCA or re-CABG. With use of the 
Cox proportional hazards model, five independent predictors of long- 
term mortality were identified for the entire group (632 patients). 
Additional variables entered that did not correlate with long-term 
mortality were gender, history of prior MI, incomplete revasculariza- 
tion, left anterior descending coronary artery disease, graft age, use of 
the internal mammary artery at reoperation, PTCA and re-CABG. 
*CCS class IV angina symptoms. LVEF -- left ventricular ejection 
fraction. 
At the time of reoperation, -25% of the surgical patients had 
functional class IV angina, which has been associated with 
increased rates of perioperative mortality and Q wave MI 
compared with those associated with elective CABG in pa- 
tients with stable angina pectoris (31-34). In addition, the 
mean interval to reoperation was 9.4 years in the patients with 
re-CABG who died, and the majority of these patients had 
angiographic evidence of extensive atherosclerosis. This ex- 
tended time frame is prognostically important; Salomon et al. 
(11) reported a procedural mortality rate of 5.8% (18 of 312) 
in patients with a reoperative interval of 1 to 10 years 
compared with a rate of 17.6% (13 of 74) for those whose 
interval between procedures was >10 years. 
The 6.1% surgical Q wave MI rate is comparable to 
previously reported rates (1,10,11,19,21,22,25-30) of 0.8% to 
11.3% for re-CABG, in diverse patient groups. The signifi- 
cantly lower Q wave MI rate in the PTCA-treated patients, 
0.9%, is consistent with data from two trials (6,7) in which 
PTCA was confined to native vessels: the recently published 
German Angioplasty Bypass Surgery Investigation (GABI) (6) 
(Q wave MI rate: PTCA 2.3% vs. CABG 8.1%, p = 0.022) and 
the Emory Angioplasty versus Surgery Trial (EAST) (Q wave 
MI rate: PTCA 3.0% vs. CABG 10.3%, p = 0.004) (7). 
Long-term outcomes. During the follow-up period, overall 
and event-free (freedom from death or myocardial infarction) 
survival rates were similar in the PTCA and re-CABG groups. 
Angina class was similar in both groups at 4 years after the 
procedure: however, as mentioned, the patients with PTCA 
required significantly more procedures than did the patients 
with re-CABG to achieve equivalent symptom relief. These 
findings are similar to previously published randomized ata 
comparing these two revascularization options in patients 
without previous CABG (5-8). 
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Limitations of the study. This study was a retrospective 
review of nonrandomized, prospectively collected data. The 
retrospective nature, <100% follow-up and potential for se- 
lection and referral bias may limit the application of these 
results to all patients who require repeat revascularization 
after an initially successful CABG procedure. Given the lack of 
a prospective, randomized comparison of these two tech- 
niques, the selection for re-CABG of patients with more 
extensive coronary disease and unfavorable anatomic features 
for percutaneous revascularization (i.e., diffuse native coronary 
atherosclerosis, degenerated saphenous vein graft disease, 
unprotected left main coronary artery stenoses, chronic total 
occlusions) may have potentially biased the results against 
re-CABG and contributed to the procedural mortality benefit 
seen with PTCA. 
Although clinical follow-up was 6 years, this interval may 
not have been long enough to reveal true differences between 
these techniques. It is possible that a preferential survival 
benefit for one of the two techniques would have evolved over 
a longer study period. Ideally, prospective, randomized trials 
are needed to confirm retrospective, nonrandomized ata; 
however, given the complexity of clinical decision making in 
patients after CABG, it may be unrealistic and economically 
prohibitive to properly complete such a study. In addition, with 
the passage of time, the performance of repeat revasculariza- 
tion procedures, often utilizing the alternative modality, dilutes 
the significance of the initial treatment stategy. 
Continued technical changes have occurred in both the 
surgical and percutaneous revascularization techniques com- 
pared with the state-of-the-art at the time of the study. 
Increasing experience with re-CABG, improved myocardial 
preservation techniques and evolving technical strategies for 
revascularization have progressively reduced procedural mor- 
bidity and mortality (21,22,25,35). In addition, the increasing 
use of arterial bypass conduits may lessen the need for repeat 
revascularization procedures and favorably alter long-term 
survival. 
Insufficient data are available to report on the economic 
impact of re-CABG and PTCA in patients with previous 
CABG. The recently published randomized trials comparing 
PTCA with CABG in patients with multivessel coronary artery 
disease suggest an early economic benefit for PTCA. However, 
this benefit is eroded over time because of the greatly in- 
creased need for repeat revascularization procedures in those 
patients treated with PTCA (5-8). It remains to be seen 
whether improved catheter designs, continued expansion of 
operator experience, synergistic application of new device 
technology, novel therapeutic strategies and use of adjunctive 
techniques such as intravascular ultrasound and intracoronary 
stent placement will improve immediate outcomes and poten- 
tially decrease the need for repeat revascularization proce- 
dures in a clinically and economically beneficial fashion (36- 
38). 
Conclusions. In this nonrandomized series of patients with 
previous CABG requiring revascularization, an initial stategy 
of either PTCA or re-CABG resulted in equivalent overall 
survival, event-free survival and relief of angina. PTCA offers 
lower procedural morbidity and mortality risks, although it is 
associated with less complete initial revascularization a d a 
greater need for subsequent revascularization procedures. This 
information, together with the specific clinical and anatomic 
features presented by the patient, should assist in the formu- 
lation of an individualized revascularization strategy that offers 
the greatest opportunity for immediate and long-term clinical 
benefit. 
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